1. Home
  2. GCTK vs TCBP Comparison

GCTK vs TCBP Comparison

Compare GCTK & TCBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GCTK
  • TCBP
  • Stock Information
  • Founded
  • GCTK 2001
  • TCBP 2013
  • Country
  • GCTK United States
  • TCBP United Kingdom
  • Employees
  • GCTK N/A
  • TCBP N/A
  • Industry
  • GCTK Medical/Dental Instruments
  • TCBP Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • GCTK Health Care
  • TCBP Health Care
  • Exchange
  • GCTK Nasdaq
  • TCBP Nasdaq
  • Market Cap
  • GCTK 5.1M
  • TCBP 5.0M
  • IPO Year
  • GCTK N/A
  • TCBP 2022
  • Fundamental
  • Price
  • GCTK $0.08
  • TCBP $0.38
  • Analyst Decision
  • GCTK
  • TCBP Strong Buy
  • Analyst Count
  • GCTK 0
  • TCBP 1
  • Target Price
  • GCTK N/A
  • TCBP $2.40
  • AVG Volume (30 Days)
  • GCTK 93.2M
  • TCBP 3.1M
  • Earning Date
  • GCTK 11-14-2024
  • TCBP 11-25-2024
  • Dividend Yield
  • GCTK N/A
  • TCBP N/A
  • EPS Growth
  • GCTK N/A
  • TCBP N/A
  • EPS
  • GCTK N/A
  • TCBP N/A
  • Revenue
  • GCTK N/A
  • TCBP N/A
  • Revenue This Year
  • GCTK N/A
  • TCBP N/A
  • Revenue Next Year
  • GCTK N/A
  • TCBP N/A
  • P/E Ratio
  • GCTK N/A
  • TCBP N/A
  • Revenue Growth
  • GCTK N/A
  • TCBP N/A
  • 52 Week Low
  • GCTK $0.06
  • TCBP $0.37
  • 52 Week High
  • GCTK $4.95
  • TCBP $32.70
  • Technical
  • Relative Strength Index (RSI)
  • GCTK 29.97
  • TCBP 30.77
  • Support Level
  • GCTK $0.06
  • TCBP $0.37
  • Resistance Level
  • GCTK $0.19
  • TCBP $0.47
  • Average True Range (ATR)
  • GCTK 0.05
  • TCBP 0.10
  • MACD
  • GCTK 0.00
  • TCBP 0.01
  • Stochastic Oscillator
  • GCTK 6.98
  • TCBP 2.65

About GCTK GlucoTrack Inc.

GlucoTrack Inc is a medical device company. It focuses on the design, development, and commercialization of non-invasive glucose monitoring devices for use by people with diabetes and pre-diabetics. The company has developed a non-invasive glucose monitor, the GlucoTrack model DF-F glucose monitoring device, which is designed to help people with diabetes and pre-diabetics obtain glucose level readings without the pain, inconvenience, and difficulty of conventional spot finger stick devices. It has completed a feasibility study successfully demonstrating that a minimum two-year implant life is highly probable with the sensor design. They have also initiated an animal study with an initial prototype system that has thus far demonstrated a simple implant procedure and good functionality.

About TCBP TC BioPharm (Holdings) plc

TC BioPharm (Holdings) PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapy products that are based on its proprietary allogeneic gamma delta T (abbreviated as GD-T) cell platform. Harnessing the innate ability of GD-Ts has enabled the company to develop a range of clinical-stage cell therapies designed to combat cancer and viral infection.

Share on Social Networks: